The brief

Analyst view

• Ribupatide Phase 2: 17.7% mean weight loss vs placebo at 48 weeks; 88% achieved ≥5% weight loss.
• Total raised: $400M Series A (2024) + $600M Series B (2025) + $500M IPO (April 2026).
• Phase 3 KaiNETIC program enrolling 4,700+ patients; oral form in development for H1 2027.

Technical approach

As reported

Dual agonism

GLP-1 and GIP receptor activation

Dual GLP-1/GIP binding reduces appetite and improves insulin secretion. The combination may exceed GLP-1-only agents in weight loss.

Once-weekly dosing

Injectable peptide convenience

A once-weekly injection offers simpler adherence than daily pills, matching the successful GLP-1 market pattern established by Ozempic and others.

Oral expansion

Small-molecule tablet version

Kailera is developing an oral tablet form of ribupatide to serve patients who prefer pills and to expand the addressable market.